Zacks Small Cap Analysis – ELTK: Eltek Studies 1st Quarter 2024 Monetary Outcomes Defend Cyber

By Thomas Kerr, CFA NASDAQ:ELTK READ THE FULL ELTK RESEARCH REPORT On Might 15, 2024, Eltek (NASDAQ:ELTK) introduced monetary outcomes for the first quarter of 2024 which have been largely in step with expectations. Revenues for the first quarter have been $11.8 million in comparison with $11.5 million within the 1st quarter of 2023. Gross … Read more

Zacks Small Cap Analysis – XFOR: XOLREMDI Permitted by FDA…

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Enterprise Replace XOLREMDI Permitted by the FDA On April 29, 2024, X4 Prescription drugs, Inc. (NASDAQ:XFOR) introduced that the U.S. Meals and Drug Administration (FDA) has authorised XOLREMDI (mavorixafor) to be used in sufferers 12 years of age and older with WHIM syndrome (warts, … Read more